March 16, 2020 / 6:06 PM / 21 days ago

BRIEF-Novo Nordisk Pauses Clinical Trials Investigating Concizumab In Haemophilia A And B

March 16 (Reuters) - Novo Nordisk A/S:

* SAYS NOVO NORDISK PAUSES CLINICAL TRIALS INVESTIGATING CONCIZUMAB (ANTI-TFPI MAB) IN HAEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS

* SAYS THREE CLINICAL TRIALS WERE INVESTIGATING CONCIZUMAB PROPHYLAXIS TREATMENT IN HAEMOPHILIA A AND B PATIENTS REGARDLESS OF INHIBITOR STATUS

* SAYS CONSEQUENTLY, NO ADDITIONAL PATIENTS WILL BE RECRUITED, AND FURTHER TREATMENT OF PATIENTS CURRENTLY ENROLLED IN TRIALS WITH CONCIZUMAB WILL CEASE

* SAYS DECISION IS A RESULT OF OCCURRENCE OF NON-FATAL THROMBOTIC EVENTS IN THREE PATIENTS ENROLLED IN ONGOING PHASE 3 PROGRAMME

* SAYS NOVO NORDISK AND AN INDEPENDENT DATA MONITORING COMMITTEE ARE CURRENTLY ASSESSING RELEVANCE OF EVENTS TO CONTINUATION OF PROGRAMME AND NO CONCLUSIONS HAVE YET BEEN MADE Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below